SINGAPORE--(BUSINESS WIRE)--Mobvista (01860. HK), a global leader in marketing and advertising technology, launches an interactive mobile ad campaign, "Recycle Hero,"...
DUBLIN--(BUSINESS WIRE)--The "A2P Messaging Market Size, Share & Trends Analysis Report By Component, By Deployment Mode, By Enterprise Size, By...
Commits $5 million over five years to support NGOs focused on replicable, sustainable and scalable projects to address climate change...
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene today announced an agreement with Hokkaido University Hospital to drive the discovery, validation and implementation of a...
Assemble international experts to navigate transition finance, social impact investments and decarbonization technologies Financial Secretary Paul Chan will give keynote...
Take on the Role of Geppetto’s Prized Puppet to Uncover the Mysteries of Krat and Save the City in this...
New Global Standards Editon of Flagship Report Analyzes Four Years of Global Data to Pinpoint Key Attributes for Maximum Impact...
Combat skill adjustments for all classes - Warrior, Lancer, Sorcerer, Taoist, Arbalist, Darkist Magic Square and Secret Peak expanded to...
To provide athletes tools for training, practice and game analysis based on NTT’s IoT, AI and ICT technologies TOKYO--(BUSINESS WIRE)--NTT...
Latest Point of Presence in the Philippines brings high-speed connectivity to this rapidly growing digital economy MANILA, Philippines--(BUSINESS WIRE)--Hurricane Electric,...
HONG KONG SAR - Media OutReach - 19 September 2023 - Alibaba Pictures Group Limited ("Alibaba Pictures" or the "Company,"...
Landmark achievement strengthens FANUC’s position as a global automation leader. ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--#EV--FANUC CORPORATION, a global leader in Factory...
Metaverse fan party with universal entertainers Lee Eun-ji, THE BOYZ, and Just Jerk K-Wonderland, a mega Korean culture event that...
European Commission approves TEVIMBRA for previously treated advanced or metastatic esophageal squamous cell carcinoma (ESCC) U.S. FDA accepts Biologics License...
First-in-human trial for DF-003, the 2nd compound from IDInVivo and MedChem5 platform to enter clinical trials GUILFORD, Conn. & SHANGHAI--(BUSINESS...
